$739 Million is the total value of Atlas Venture Life Science Advisors, LLC's 16 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 5.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| KYMR | Sell | Kymera Therapeutics, Inc. | $173,580,303 | +16.2% | 5,858,262 | -2.1% | 23.50% | +30.6% |
| DYN | Buy | Dyne Therapeutics, Inc. | $113,880,372 | -0.4% | 9,885,449 | +0.2% | 15.42% | +11.9% |
| DAWN | Buy | Day One Biopharmaceuticals, Inc. | $101,724,228 | -37.5% | 7,608,394 | +0.5% | 13.77% | -29.8% |
| Disc Medicine, Inc. | $73,355,203 | +6.5% | 3,461,784 | 0.0% | 9.93% | +19.7% | ||
| Vigil Neuroscience, Inc. | $57,142,996 | -21.7% | 5,836,874 | 0.0% | 7.74% | -12.0% | ||
| Third Harmonic Bio, Inc. | $44,940,379 | -4.2% | 10,907,859 | 0.0% | 6.08% | +7.7% | ||
| AVTE | Buy | Aerovate Therapeutics, Inc. | $41,131,652 | -30.4% | 2,039,249 | +1.1% | 5.57% | -21.8% |
| REPL | Replimune Group, Inc. | $37,055,978 | -35.1% | 2,098,300 | 0.0% | 5.02% | -27.0% | |
| GBIO | Buy | Generation Bio, Co. | $35,601,781 | +9.4% | 8,279,484 | +0.0% | 4.82% | +23.0% |
| AKRO | Akero Therapeutics, Inc. | $22,736,043 | -30.2% | 594,251 | 0.0% | 3.08% | -21.5% | |
| IKNA | Ikena Oncology, Inc. | $17,312,714 | +29.7% | 5,018,178 | 0.0% | 2.34% | +45.8% | |
| Xilio Therapeutics, Inc. | $8,747,120 | +17.8% | 2,759,344 | 0.0% | 1.18% | +32.4% | ||
| AVRO | Buy | AvroBio, Inc. | $4,541,381 | +40.9% | 4,541,381 | +0.5% | 0.62% | +58.5% |
| MGTA | Buy | Magenta Therapeutics, Inc. | $3,013,262 | +119.4% | 3,791,698 | +9.1% | 0.41% | +147.3% |
| VRDN | Viridian Therapeutics, Inc. | $2,291,432 | -12.9% | 90,072 | 0.0% | 0.31% | -2.2% | |
| SPRO | Spero Therapeutics, Inc. | $1,495,182 | -16.2% | 1,031,160 | 0.0% | 0.20% | -6.0% | |
| FSTX | Exit | F-star Therapeutics, Inc. | $0 | – | -599,524 | -100.0% | -0.46% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Kymera Therapeutics, Inc. | 8 | Q3 2023 | 40.1% |
| Day One Biopharmaceuticals, Inc. | 8 | Q3 2023 | 26.8% |
| Dyne Therapeutics, Inc. | 8 | Q3 2023 | 15.4% |
| Replimune Group, Inc. | 8 | Q3 2023 | 9.4% |
| Generation Bio, Co. | 8 | Q3 2023 | 9.1% |
| Aerovate Therapeutics, Inc. | 8 | Q3 2023 | 7.2% |
| Akero Therapeutics, Inc. | 8 | Q3 2023 | 4.3% |
| Ikena Oncology, Inc. | 8 | Q3 2023 | 5.8% |
| Xilio Therapeutics, Inc. | 8 | Q3 2023 | 4.1% |
| AVROBIO INC | 8 | Q3 2023 | 1.6% |
View Atlas Venture Life Science Advisors, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-09 |
| 13F-HR | 2022-08-03 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-05-16 |
View Atlas Venture Life Science Advisors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.